Pictet Asset Management SA Purchases 4,493 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR)

Pictet Asset Management SA raised its position in shares of Vir Biotechnology, Inc. (NASDAQ:VIRGet Rating) by 10.0% in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 49,243 shares of the company’s stock after purchasing an additional 4,493 shares during the quarter. Pictet Asset Management SA’s holdings in Vir Biotechnology were worth $1,254,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of VIR. SG Americas Securities LLC increased its stake in Vir Biotechnology by 1,115.8% during the 1st quarter. SG Americas Securities LLC now owns 33,751 shares of the company’s stock valued at $868,000 after purchasing an additional 30,975 shares in the last quarter. Victory Capital Management Inc. boosted its holdings in shares of Vir Biotechnology by 96.2% during the 1st quarter. Victory Capital Management Inc. now owns 20,545 shares of the company’s stock valued at $418,000 after acquiring an additional 10,073 shares during the last quarter. ClariVest Asset Management LLC boosted its holdings in shares of Vir Biotechnology by 47.9% during the 1st quarter. ClariVest Asset Management LLC now owns 143,717 shares of the company’s stock valued at $3,696,000 after acquiring an additional 46,574 shares during the last quarter. Russell Investments Group Ltd. boosted its holdings in shares of Vir Biotechnology by 98.2% during the 1st quarter. Russell Investments Group Ltd. now owns 44,669 shares of the company’s stock valued at $1,148,000 after acquiring an additional 22,127 shares during the last quarter. Finally, Sector Gamma AS boosted its holdings in shares of Vir Biotechnology by 82.3% during the 1st quarter. Sector Gamma AS now owns 80,223 shares of the company’s stock valued at $2,063,000 after acquiring an additional 36,223 shares during the last quarter. 64.55% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. Needham & Company LLC dropped their price target on shares of Vir Biotechnology from $35.00 to $32.00 and set a “buy” rating on the stock in a report on Friday, November 4th. Barclays dropped their price objective on shares of Vir Biotechnology to $67.00 in a report on Monday, August 15th. SVB Leerink raised their price objective on shares of Vir Biotechnology from $40.00 to $45.00 and gave the stock an “outperform” rating in a report on Friday, November 4th. Morgan Stanley raised their price objective on shares of Vir Biotechnology from $15.00 to $18.00 and gave the stock an “underweight” rating in a report on Friday, November 4th. Finally, TheStreet raised shares of Vir Biotechnology from a “d” rating to a “c-” rating in a report on Monday, October 10th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat, Vir Biotechnology has an average rating of “Hold” and an average target price of $52.50.

Vir Biotechnology Trading Up 2.7 %

NASDAQ VIR opened at $27.41 on Wednesday. Vir Biotechnology, Inc. has a 12 month low of $18.05 and a 12 month high of $58.00. The stock has a market cap of $3.65 billion, a price-to-earnings ratio of 3.23 and a beta of -0.01. The company’s 50 day moving average is $22.18 and its two-hundred day moving average is $24.48.

Insiders Place Their Bets

In other Vir Biotechnology news, major shareholder Endurance (Cayman) Ltd Svf sold 25,259 shares of the firm’s stock in a transaction that occurred on Friday, November 18th. The shares were sold at an average price of $27.21, for a total transaction of $687,297.39. Following the sale, the insider now owns 21,243,198 shares in the company, valued at approximately $578,027,417.58. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other Vir Biotechnology news, major shareholder Endurance (Cayman) Ltd Svf sold 25,259 shares of the firm’s stock in a transaction that occurred on Friday, November 18th. The shares were sold at an average price of $27.21, for a total transaction of $687,297.39. Following the sale, the insider now owns 21,243,198 shares in the company, valued at approximately $578,027,417.58. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Vicki L. Sato sold 17,915 shares of Vir Biotechnology stock in a transaction that occurred on Tuesday, November 8th. The shares were sold at an average price of $27.38, for a total transaction of $490,512.70. Following the sale, the director now owns 1,399,004 shares in the company, valued at approximately $38,304,729.52. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 262,875 shares of company stock worth $6,954,888. Company insiders own 22.40% of the company’s stock.

About Vir Biotechnology

(Get Rating)

Vir Biotechnology, Inc, a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus.

Featured Stories

Want to see what other hedge funds are holding VIR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vir Biotechnology, Inc. (NASDAQ:VIRGet Rating).

Institutional Ownership by Quarter for Vir Biotechnology (NASDAQ:VIR)

Receive News & Ratings for Vir Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vir Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.